U.S. License Holder:
Date of License:
GAZYVA (obinutuzumab) is a CD20-directed cytolytic antibody and is indicated:
In combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia;
In combination with bendamustine followed by Gazyva monotherapy, for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen
In combination with chemotherapy followed by Gazyva monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.